Enliven Therapeutics, Inc. $ELVN Shares Purchased by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in Enliven Therapeutics by 61.3%, owning approximately 0.43% of the company worth $4.17 million as of its latest filing.
• Multiple analysts have recently raised their price targets for Enliven Therapeutics, with an average target of $41.20 and ratings predominantly reflecting a "Buy" sentiment.
• Recent insider trading saw CFO Benjamin Hohl and CEO Samuel Kintz sell shares, indicating a 12.38% and 1.11% decrease in their respective ownership positions.

Goldman Sachs Group Inc. grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 61.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 211,752 shares of the company's stock after acquiring an additional 80,506 shares during the quarter. Goldman Sachs Group Inc. owned about 0.43% of Enliven Therapeutics worth $4,167,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Enliven Therapeutics by 148,550.7% in the first quarter. Russell Investments Group Ltd. now owns 105,542 shares of the company's stock valued at $2,077,000 after purchasing an additional 105,471 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at approximately $2,049,000. Ameriprise Financial Inc. acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $789,000. Jane Street Group LLC acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at approximately $578,000. Finally, Ally Bridge Group NY LLC increased its stake in Enliven Therapeutics by 19.8% during the first quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company's stock worth $3,341,000 after acquiring an additional 28,064 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on ELVN. HC Wainwright raised their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Robert W. Baird lifted their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. Finally, The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $41.20.

Insider Transactions at Enliven Therapeutics

In other news, COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $20.24, for a total value of $134,940.08. Following the completion of the sale, the chief operating officer directly owned 283,308 shares of the company's stock, valued at approximately $5,734,153.92. The trade was a 2.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samuel Kintz sold 5,000 shares of the business's stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $19.09, for a total value of $95,450.00. Following the completion of the transaction, the chief executive officer owned 922,892 shares in the company, valued at $17,618,008.28. This trade represents a 0.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 85,234 shares of company stock valued at $1,756,514 over the last quarter. Company insiders own 25.90% of the company's stock.

Enliven Therapeutics Stock Performance

NASDAQ ELVN traded down $0.96 during trading on Friday, reaching $18.96. 2,310,053 shares of the company's stock were exchanged, compared to its average volume of 597,869. The stock has a market cap of $1.12 billion, a P/E ratio of -9.48 and a beta of 0.88. The company has a 50 day moving average price of $20.11 and a two-hundred day moving average price of $19.64. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. Research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.